| Year |
Citation |
Score |
| 2021 |
Shen H, Chang C, Ing P, Cook K, McKelvey K, Lai J, Gloss B, Prior V, O'Neill G, Blackburn A, Gee H, Hau E. EXTH-41. IMPROVING THE RADIOSENSITIVITY OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG) BY TARGETING HYPOXIA AND MITOCHONDRIAL METABOLISM Neuro-Oncology. 23: vi172-vi172. DOI: 10.1093/neuonc/noab196.680 |
0.301 |
|
| 2020 |
Dhawan A, Scott J, Sundaresan P, Veness M, Porceddu S, Hau E, Harris AL, Buffa FM, Gee HE. Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports. 10: 10226. PMID 32576885 DOI: 10.1038/S41598-020-66983-X |
0.359 |
|
| 2020 |
Shen H, Chang C, Gee H, McKelvey K, O’Neill G, Prior V, Blackburn A, Hau E. DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG) Neuro-Oncology. 22: iii289-iii289. DOI: 10.1093/neuonc/noaa222.063 |
0.329 |
|
| 2018 |
Dhawan A, Scott JG, Sundaresan P, Veness M, Porceddu S, Hau E, Ahern V, Harris AL, Buffa FM, Gee HE. Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene signature predictors of outcome in oropharynx head and neck cancers. Journal of Clinical Oncology. 36: e18046-e18046. DOI: 10.1016/J.Ijrobp.2018.06.338 |
0.335 |
|
| 2018 |
Dhawan A, Scott J, Sundaresan P, Veness M, Porceddu S, Hau E, Ahern V, Harris A, Buffa F, Gee H. Are Signatures of Radiosensitivity Ready for Routine Clinical Use? a Pragmatic Comparison of Clinical, Pathological and Gene Signature Predictors of Outcome in Oropharynx Head and Neck Cancers International Journal of Radiation Oncology*Biology*Physics. 102: S137-S138. DOI: 10.1016/j.ijrobp.2018.06.338 |
0.335 |
|
| 2017 |
Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, Zaratzian A, Carroll S, Toohey J, O'Toole SA, Harris AL, ... ... Gee HE, et al. miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Research. PMID 29180477 DOI: 10.1158/0008-5472.CAN-16-3105 |
0.582 |
|
| 2015 |
Zhang X, Gee H, Rose B, Lee CS, Clark J, Elliott M, Gamble JR, Cairns MJ, Harris A, Khoury S, Tran N. Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. Bmc Cancer. 16: 86. PMID 26867589 DOI: 10.1186/s12885-016-2109-4 |
0.549 |
|
| 2015 |
Gee HE, Buffa FM, Harris AL, Toohey JM, Carroll SL, Cooper CL, Beith J, McNeil C, Carmalt H, Mak C, Warrier S, Holliday A, Selinger C, Beckers R, Kennedy C, et al. MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. International Journal of Radiation Oncology, Biology, Physics. 93: 1104-14. PMID 26581147 DOI: 10.1016/j.ijrobp.2015.08.046 |
0.409 |
|
| 2013 |
Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, Buffa F, Huffman M, Sinn AL, Silver J, Turley H, Leek R, Harris AL, Ivan M. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine (Berlin, Germany). 91: 749-58. PMID 23361368 DOI: 10.1007/s00109-013-0996-2 |
0.559 |
|
| 2011 |
Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Research. 71: 5635-45. PMID 21737487 DOI: 10.1158/0008-5472.CAN-11-0489 |
0.74 |
|
| 2011 |
Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer. 104: 1168-77. PMID 21407217 DOI: 10.1038/sj.bjc.6606076 |
0.494 |
|
| 2010 |
Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. Plos One. 5: e10345. PMID 20436681 DOI: 10.1371/Journal.Pone.0010345 |
0.552 |
|
| 2010 |
Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 116: 2148-58. PMID 20187102 DOI: 10.1002/cncr.25009 |
0.738 |
|
| 2008 |
Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J, Harris AL. MicroRNA-10b and breast cancer metastasis. Nature. 455: E8-9; author reply E. PMID 18948893 DOI: 10.1038/nature07362 |
0.393 |
|
| Show low-probability matches. |